P. Rugman

发表

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

Christopher E Brightling, Ian D Pavord, Michael R Barer, 2011, American journal of respiratory and critical care medicine.

Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD

R. Stockley, E. Sapey, N. Snell, 2009, Journal of Clinical Immunology.

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma

E. Bateman, S. Ivanov, Mohib Uddin, 2018, Drug design, development and therapy.

Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease

B. Hargadon, C. Brightling, M. Bafadhel, 2011, Respiration.

COPD Cytokines IL-17 A and IL-17 F in Asthma and Expression of the T Helper 17-Associated

M. Bafadhel, M. Sleeman, S. Siddiqui, 2010 .

The Sensitivity and Specificity of Peripheral Blood Eosinophilia To Predict Sputum Eosinophilia in COPD Subjects

C. Brightling, M. Bafadhel, V. Mistry, 2009, Asian Test Symposium.

Acute Exacerbations of COPD: Identification of Biological Clusters and Their Biomarkers

I. Pavord, K. Lindblad, S. Johnston, 2011 .

Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease

I. Pavord, P. Burton, C. Newby, 2015, The Journal of allergy and clinical immunology.

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.

H. Gevensleben, Y. Drew, R. Plummer, 2020, Cancer discovery.

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

Y. Drew, R. Plummer, N. Tunariu, 2016 .

AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

S. Chandarlapaty, A. Oza, J. Baselga, 2015 .

Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles

I. Pavord, S. Johnston, C. Brightling, 2018, Journal of Allergy and Clinical Immunology.

Monocarboxylate transporter MCT1 is a target for immunosuppression

A. Ross, Leslie R Evans, A. Jackson, 2005, Nature chemical biology.

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, inAkt1E17K mutation positive advanced solid tumors

S. Chandarlapaty, A. Oza, J. Baselga, 2015 .

Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

D. Rea, J. Robertson, K. Cheung, 2019, Clinical Cancer Research.

Capivasertib (AZD5363), an AKT inhibitor, rapidly and effectively targets key AKT pathway and proliferation biomarkers: the STAKT pre-surgical breast cancer study

D. Rea, J. Robertson, K. Cheung, 2019 .

A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

J. Schellens, U. Banerji, P. Lawrence, 2018, Cancer Chemotherapy and Pharmacology.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

J. Barrett, J. Schellens, P. Elvin, 2017, Clinical Cancer Research.

Lateral diffusion of proteins in the periplasm of Escherichia coli

M. Foley, C. Higgins, P. Garland, 1986, Journal of bacteriology.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

K. Tamura, C. Corcoran, G. Schiavon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD

C. Brightling, M. Bafadhel, M. Sleeman, 2010, Chest.

Structure-based design of peptidomimetic antagonists of p56lck SH2 domain

I. E. Smith, N. Borkakoti, D. Banner, 2002 .

Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPD

I. Pavord, C. Brightling, M. Bafadhel, 2009, Respiration.

Biological exacerbation clusters demonstrate asthma and COPD overlap with distinct mediator and microbiome profiles

I. Pavord, S. Johnston, C. Brightling, 2018 .

Alternative modes of binding of proteins with tandem SH2 domains

M. Waterfield, J. Ladbury, P. Driscoll, 2008, Protein science : a publication of the Protein Society.

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients.

A. Reuss, A. Okamoto, S. Lheureux, 2019, Journal of Clinical Oncology.

Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a Haemophilus‐predominant subgroup

I. Pavord, C. Brightling, M. Barer, 2019, Allergy.

Acute exacerbations of COPD: identification of biological clusters and their

I. Pavord, K. Lindblad, S. Johnston, 2011 .

A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers.

J. Schellens, P. Elvin, G. Batist, 2015 .

Effects of anaerobic regulatory mutations and catabolite repression on regulation of hydrogen metabolism and hydrogenase isoenzyme composition in Salmonella typhimurium

C. Higgins, R. Sawers, D. Boxer, 1986, Journal of bacteriology.